Oura reaches $11 billion valuation with new $900 million fundraise

Oura reaches  billion valuation with new 0 million fundraise


The Oura Ring 4

Courtesy: Oura

Oura said Tuesday that it raised over $900 million in a new Series E funding round, bringing the company’s valuation to $11 billion.

The fundraise, led by Fidelity Management & Research Company, also includes new investor ICONIQ and contributions from Whale Rock and Atreides.

“With this investment, we will accelerate innovation, expand our global reach, and set a new standard for what wearables can achieve in advancing preventive health,” said CEO Tom Hale in a statement.

The Finnish company, which ranked No. 23 on CNBC’S 2025 Disruptor 50 List, has raised approximately $1.5 billion, according to a release.

Known for its Oura Rings, the company competes with other smart ring makers like Samsung and RingConn, as well as fitness-focused devices from Whoop and Garmin.

Oura announced in September that it has sold over 5.5 million Oura Rings since the product’s launch in 2015, a significant jump from 2.5 million rings announced in June 2024. The company reported revenue of over $500 million in 2024, more than double from the year prior, and expects to reach $1 billion in sales this year.

Looking to broaden further in the wearable category, Oura has also been expanding its features to compete with more general wearable devices like Apple or Samsung watches.

Along with its new Oura Ring 4 Ceramic, the company recently unveiled Health Panels, a blood testing feature that allows users to schedule and view their lab results directly in the Oura App.

Users can keep track of up to 50 biomarkers and can receive their health data summary as well as diet or activity suggestions from Oura’s AI-powered Advisor.

The ring maker also partnered with Dexcom, a leader in glucose monitoring technology, late last year to integrate Dexcom glucose data with biometrics collected by Oura so users can monitor their glucose levels.

“We’re proud to be building not just a product, but a global movement toward proactive health—helping people understand their bodies, make better lifestyle decisions, and connect more effectively with their healthcare providers,” Hale said.



Source

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
Health

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]

Read More
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More